Clinical Trials Browser

Withdrawn × Sarcoma, Synovial × Clear all

NCT05116800 2021-12-07

Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma

Phase 2 Withdrawn

Bone Neoplasms, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT04906876 2021-07-28

A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas

Phase 2 Withdrawn

Bone Neoplasms, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT03697824 2019-10-29

Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a

Phase 2 Withdrawn

Neoplasms, Sarcoma, Synovial

NCT03773510 2019-05-13

TRADITIONS

Phase 3 Withdrawn

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial

NCT02059850 2016-02-03

NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Phase 1 Withdrawn

Sarcoma, Sarcoma, Synovial, Liposarcoma, Myxoid